Micro-RNA: biomarker for the treatment of cancer

  • Vanashri Nawale Department of Pharmaceutics, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422 213, Maharashtra, India
  • Avinash Darekar Department of Pharmaceutics, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422 213, Maharashtra, India
  • Ravindranath Saudagar Department of Pharmaceutical chemistry, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422 213, Maharashtra, India

Abstract

MicroRNAs (miRNAs) are presently experiencing a renewed height of attention not simplest as diagnostics, however specifically as noticeably promising novel objectives or gear for medical therapy in several different malignant diseases. MicroRNAs have emerged as key publish-transcriptional regulators of gene expression, involved in diverse physiological and pathological approaches. It changed into located that several miRNAs are without delay worried in human cancers, along with lung, breast, mind, liver, colon most cancers and leukemia. Biomarkers have many capacity packages in oncology, together with danger assessment, screening, differential analysis, dedication of analysis, prediction of reaction to treatment, and tracking of progression of disease. In this evaluation, we summarize the present day know-how and ideas concerning the involvement of microRNAs in cancer, which have emerged from the take a look at of cellular tradition and animal model systems, which includes the regulation of key cancer-related pathways, which include mobile cycle control and the DNA damage response. Importantly, microRNA molecules are already getting into the health facility as diagnostic and prognostic biomarkers for patient stratification and also as therapeutic targets and marketers.


Keywords: MiRNA, Biomarkers, cancer.

Downloads

Download data is not yet available.

Author Biographies

Vanashri Nawale, Department of Pharmaceutics, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422 213, Maharashtra, India

 Department of Pharmaceutics, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422 213, Maharashtra, India

Avinash Darekar, Department of Pharmaceutics, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422 213, Maharashtra, India

 Department of Pharmaceutics, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422 213, Maharashtra, India

Ravindranath Saudagar, Department of Pharmaceutical chemistry, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422 213, Maharashtra, India

Department of Pharmaceutical chemistry, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422 213, Maharashtra, India

References

1. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993; 75(5):843-854.
2. Colles P, Jianjun C, MicroRNAs in cancer biology and therapy: Current status and perspectives, Genes and Diseases, 2014, 1, 53-63.
3. Berindan-Neagoe I., Monroig Pdel C., Pasculli B., Calin G.A., MicroRNAome genome: a treasure for cancer diagnosis and therapy, CA Cancer J. Clin, 2014; 64:311–336.
4. Shah MY, Ferrajoli A, Sood AK, Gabriel Lopez-Berestein, George A. Calin microRNA Therapeutics in cancer – An Emerging concept, EBioMedicine, 2016; 12:34-42.
5. Grimson A, Srivastava M, Fahey B, et al. Early origins and evolution of microRNAs and Piwi-interacting RNAs in animals, Nature, 2008; 455:1193–1197.
6. Scholer N, Langer C, Dohner H, Buske C, and Florian Kuchenbauer, Serum microRNAs as a novel class of biomarkers: a comprehensive review of the literature. Experimental Hematology, 2010; 38:1126–1130.
7. Almeida MI, Reis RM, Calin GA. MicroRNA history: Discovery, recent applications, and next frontiers, Mutation Research, 2011; 717:1– 8.
8. Kraus VB, Burnett B, Coindreau J, Cottrell S, Eyre D, Gendreau M, Gardiner J, Garnero P, Hardin J, Henrotin Y, Heinegard D, Ko A, Lohmander LS, Matthews G, Menetski J, Moskowitz R, Persiani S, Poole AR, Rousseau JC, Todman M, OARSI FDA Osteoarthritis Biomarkers Working Group, Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis, Osteoarthritis and Cartilage, 2011; 19:515-542.
9. Ferlay J, Bray F, and Pisani DM, Globocon 2000: Cancer Incidence Mortality and Prevalence Worldwide 1(5), IARC Press, Lyon, France, 2001.
10. Parkin DM, Bray F, Ferlay J, and Pisani P, “Global cancerstatistics, 2002,” CA–A Cancer Journal for Clinicians, 2015; 55:74-108.
11. Behne T, Sitki Copur M, Biomarkers for Hepatocellular Carcinoma. International Journal of Hepatology. Volume 2012.
12. Duffy MJ. Role of tumor markers in patients with solid cancers: a critical review, Eur J Intern Med. 2007; 18:175–184.
13. Suzuki H, Maruyama R, Yamamoto E, Kai M; DNA methylation and microRNA dysregulation in cancer, Molecular Oncology, 2012; 6:567-578.
14. Ando T., Yoshida T., Enomoto, S., Asada K., Tatematsu M., Ichinose M., Sugiyama T., Ushijima T., DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int. J. Cancer, 2009; 124:2367-2374.
15. Jansson MD, Lund AH, MicroRNA and cancer, Molecular Oncology, 2012; 6:590-610.
16. Cheng G, Circulating miRNAs: Roles in cancer diagnosis, prognosis and therapy, Advanced Drug Delivery Review, 2015; 18:75-93.
17. Lee YS, Dutta A, MicroRNAs in cancer, Annu. Rev. Pathol. 2009; 4:199–227.
18. Melo SA, Esteller M; Dysregulation of microRNAs in cancer: Playing with fire FEBS Letters, 2011; 585:2087–2099.
19. Vasudevan, S., Tong, Y. and Steitz, J.A., Switching from repression to activation: microRNAs can up-regulate translation, Science, 2007; 318:1931–1934.
20. Hayes J, Peruzzi PP, and Lawler S, MicroRNAs in cancer: biomarkers, functions and therapy, 2014; 8:460-469.
Statistics
31 Views | 48 Downloads
How to Cite
Nawale, V., Darekar, A., & Saudagar, R. (2019). Micro-RNA: biomarker for the treatment of cancer. Journal of Drug Delivery and Therapeutics, 9(2-s), 511-524. https://doi.org/10.22270/jddt.v9i2-s.2464